Bridging the Gap: Launching liquidbiopsyinfo.com
LIQOMICS introduces liquidbiopsyinfo.com, a structured, evidence-based resource for liquid biopsy applications. Plus, our latest study on ctDNA-MRD in Hodgkin lymphoma is now published in Blood.
Our Goal
Improving Cancer Treatment
At LIQOMICS, we strive to improve cancer treatment. Using a simple blood sample, we analyze circulating tumor DNA (ctDNA) to understand the genetic characteristics of individual tumors. With this liquid biopsy, genetic changes in a tumor can be detected and the amount of remaining tumor can be determined very precisely.
Liquid Biopsy
Non-invasive diagnostics through circulating tumor DNA analysis
MRD Monitoring
Precise detection of minimal residual disease after therapy
Innovative Research
Research and product development in cell-free DNA
What is Minimal Residual Disease (MRD)?
Minimal Residual Disease (MRD), also known as measurable residual disease, refers to the small population of cancer cells that may remain in the body after treatment, such as chemotherapy, radiation therapy, or surgery. These remaining cancer cells are not detectable by conventional imaging methods such as CT or MRI, but can lead to relapse.
MRD status is an important prognostic marker in various cancer types, particularly in hematologic malignancies such as leukemias and lymphomas, but increasingly also in solid tumors. Detection of MRD is very helpful for assessing therapy response, predicting relapses, and individualizing treatment.
MRD diagnostics using liquid biopsy analyzes circulating tumor DNA (ctDNA) in blood and enables non-invasive, repeatable monitoring of disease progression. Compared to other methods, ctDNA-based MRD detection is much gentler for patients and can be performed more frequently.
Note: Detailed information on clinical studies, sensitivity/specificity and scientific evidence can be found on our page for doctors and in our publications.
Our Technology
Liquid Biopsy
Our liquid biopsy platform differs from other providers. We use duplex sequencing, gene enrichment tailored to specific tumor diseases, and proprietary bioinformatics for the highest sensitivity and specificity in genotyping and measuring minimal residual disease (MRD).
What is liquid biopsy and how does it help patients?
Liquid biopsy is a revolutionary, minimally invasive method for cancer diagnostics and monitoring. Unlike traditional tissue biopsies that require surgical intervention, we only need a simple blood sample - like a normal blood test at the doctor's office.
Cancer cells continuously release small DNA fragments (ctDNA) into the bloodstream. This circulating tumor DNA contains the same genetic changes as the tumor itself. By analyzing this ctDNA, we can:
- Genetically characterize the tumor without surgery
- Monitor therapy effectiveness in real time
- Detect minimal residual disease after treatment
- Identify cancer relapse at an early stage
- Enable personalized therapy recommendations
For patients, this can mean: less burdensome examinations, more precise therapy decisions and better treatment outcomes.
Our Services
Products & Services
We support patients and their doctors with diagnostic tests and the pharmaceutical industry with research services
LymphoVista
CancerVista
Highly sensitive and specific ctDNA-based MRD test for solid tumors
- Applicable to multiple forms of solid tumors
- In-house IVD
- Technically validated
MRD Diagnostics
Precise detection of minimal residual disease for various cancer types
- Solid tumors
- Hematologic malignancies
- Therapy monitoring
- Early recurrence detection
Research Services
Support for clinical trials and drug development
- Biomarker development
- Companion diagnostics
- Study support
- Custom assays
We’re Here to Support You
Do you have questions about our products and services? We are happy to advise you on your individual requirements.
Latest News
The latest developments in research and product development
New Diagnostic Recommendations in the USA for Lymphoma Treatment
With the latest NCCN Guidelines, ctDNA-MRD testing has been officially recommended for DLBCL patients. Discover how this liquid biopsy innovation is reducing unnecessary biopsies and clarifying PET-positive findings.
Minimal Residual Disease (MRD) Measurement in Solid Tumors: Current Study Landscape
Solid tumors are abnormal tissue masses that develop in organs due to uncontrolled cell growth. Traditional biopsies have limitations, driving the development of minimally invasive liquid biopsies. This article explores current data on liquid biopsy-based MRD assessment in colorectal cancer, breast cancer, and lung cancer.
References
1 Mattlener et al. Presentation at American Society of Hematology (ASH) Annual Meeting 2024
2 Schleifenbaum et al. Presentation at European Hematology Association (EHA) Annual Meeting 2024